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CHAPTER 1

INTRODUCTION
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1.1 STAPHYLOCOCCUS AUREUS
Staphylococcus aureus (S. aureus) is a gram-positive bacterium that is both a common
commensal on human skin, colonizing approximately 30-50% of healthy adults, as well as a
major human pathogen 1,2. The bacterium was first discovered in pus from surgical abscesses in
the 1880s by Dr. Alexander Ogston. He noted a spherical shaped microorganism frequently
present in the pus in abundant clusters resembling “bunches of grapes”, to which he gave the
name: staphylococcus (a Greek term translating to bunches of grapes)3. From this observation,
he hypothesized that the staphylococci may be responsible for tissue inflammation and
suppuration. Applying Koch’s postulates, he injected pus containing the staphylococci into
animals and observed the same abscess formation in these animals as he had observed in the
surgical wound sites. He also found that no abscesses formed when injecting animals with pus
where staphylococci were absent, further confirming his hypothesis. A few years later, a German
physician, Friedrich Rosenbach, differentiated this strain from other staphylococci strains by the
golden hue of the colonies, giving its final name, Staphylococcus aureus (aureus from the Latin
term, gold) which roughly translates to “golden grapes” 4. In addition to the gold pigmentation,
other differentiating elements include coagulase positivity and mannitol fermentation 2.
Despite the important implications in skin infection and bacteremia originally described
by Dr. Ogston, the pathophysiology of S. aureus remained poorly understood and understudied
for the next couple decades. Staphylococcal research began to gain more traction with about one
publication per year by the beginning of the 20th century, however, between 2010-2020, an
average of 2,000 articles per year were published, making staphylococcus currently the most
researched bacterium 4. Penicillin was introduced in the 1960s that initially worked well in
controlling infection however quickly became an evolutionary highlight for the bug. Though
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initially successful in combating infections, treating patients became increasingly difficult as S.
aureus strains gained resistance to antimicrobial treatments such as methicillin 4,5,6. Methicillin
resistant S. aureus strains (MRSA) were at first mostly a hospital acquired infection – affecting
elderly patients, patients with comorbidities or patients infected through foreign-body and
medical devices 1,5. However, by the mid-1990s there was a sharp rise in the general population
contracting MRSA infections, creating a public health crisis in U.S. emergency departments and
other clinical settings. The community-acquired MRSA strains (CA-MRSA), such as USA300,
were found to be genetically distinct and more virulent as compared to the hospital-acquired
MRSA strains, with the ability to cause a wide range of infections in otherwise healthy people 5.
Though minor skin and soft tissue infections are most common, CA-MRSA is also a leading
cause of severe and life-threatening sepsis, necrotizing fasciitis and bacterial pneumonia. In the
early 2000s over 11 million people were infected with drug-resistant S. aureus each year, causing
more than 500,000 hospitalizations and more than 20,000 deaths per year from severe infection.
These incidents generated a massive economic burden, with an estimated annual cost between
$8.7 billion to $14.5 billion from 1998 to 2003 7. Although this rate has declined over the past
decade, mortality from severe infections remain at 20% and the CDC identified MRSA as one of
the top 18 pathogens requiring immediate attention, listing it as a “serious threat” in the
Antibiotic Resistance Threats in the United States, 2019 report 8,9.
Two major hurdles for controlling S. aureus infections are the need for novel therapies
and innovative vaccine design. Currently, vancomycin and daptomycin are the most effective
FDA approved antibiotics to combat MRSA, however, rare cases of strains with reduced
susceptibility and low-level resistance to these drugs have been observed in some clinical
isolates5. Due to its proven ability to gain multidrug resistance, it is imperative to develop non-
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antibiotic therapeutics to reduce mortality and morbidity 1,5. While the clinical consequences of
other pathogens have been mitigated through successful vaccination strategies, S. aureus poses
many unique challenges. Over the past decade, vaccines designed to prevent invasive S. aureus
infection have failed in human clinical trials, despite a variety of approaches 5,10.
Both the commensal and opportunistic nature of this bacterium have contributed to its
success as a human pathogen. In contrast to other human pathogens where colonization is
transient, S. aureus has evolved to coexist with humans in order to maintain persistent
colonization. Remarkably, approximately 20% of the healthy human population is persistently
colonized with S. aureus on the epidermal layers of skin, while 80% are intermittently
colonized11. “Infections are initiated when a breach of the skin or mucosal barrier allows
staphylococci access to adjoining tissues or the bloodstream. Whether an infection is contained
or spreads depends on a complex interplay between S. aureus virulence determinants and host
defense mechanisms” 2. A major advantage for this pathogen is the arsenal of virulence factors
with the ability to disarm both innate and adaptative immune responses resulting in a broader
range of infections.
Types of virulence factors S. aureus utilizes are membrane damaging toxins, enzymes,
cell-wall anchored proteins and anti-immune system factors to target antibodies and complement
factors. Together these virulence factors can disarm both the innate and adaptive immune
responses 2,10. For example, Panton Valentine Leukocidin (PVL), Chemotaxis Inhibitor Protein
of S. aureus (CHIPS) and Staphylococcal Complement Inhibitor (SCIN) all disrupt innate
immunity defenses. PVL is a pore-forming cytotoxin that can lyse neutrophils through the
binding of complement receptors C5aR and C5L2 on the surface of neutrophils. CHIPS and
SCIN both inhibit different aspects of the complement cascade, dampening neutrophil activation,
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recruitment and opsonin-induced neutrophil killing 13,14,15. The cell-wall anchored protein,
Staphylococcal Protein A (SpA) is a multifunctional protein and one of three S. aureus proteins
that interfere with immunoglobulin function. SpA promotes escape from neutrophil phagocytosis
by binding the Fc portion of host immunoglobulins IgG. This binding interaction positions the
immunoglobulins in an abnormal orientation, creating a protective coating over the bacteria and
rendering them unrecognizable to neutrophils. An alternative binding site on SpA can also act as
a B cell superantigen to dampen adaptive immune responses. SpA binding to the Fab region of
IgM B cell receptors activates clonal expansion, triggering production of plasma B cells to
almost exclusively recognize protein A, thus acting as a decoy antigen and biasing the immune
response away from other S. aureus virulence factors. In addition, the alternative SpA binding
site also binds to other VH3+ B cell receptors and initiates activation-induced apoptosis of B cells,
reducing antibody production and the ability to mount an effective adaptive immune
response5,13,15,16. Furthermore, it is speculated that superantigens such as enterotoxin B, also
subverts adaptive immunity by inducing T-cell tolerance and receptor anergy 17.
In addition to PVL, S. aureus also secretes an array of diverse cytolytic toxins such as the
bi-component leukocidins, hemolysins and phenol-soluble modulins (PSMs) that can lyse and
disrupt cell membrane integrity. Toxin sensitive cell types include immune cells, epithelial and
endothelial cells, platelets and erythrocytes 16,17,18. Of the S. aureus virulence factors, alphahemolysin also known as alpha-toxin (a-toxin) or Hla, is one of the most prominent and best
characterized due to its critical role in S. aureus disease pathogenesis 19.
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1.2 Staphylococcus aureus: alpha-toxin
Historic Studies
The role of the a-toxin in human disease was highly debated for a few decades, however,
nearly a century worth of studies has identified it as one of the most significant virulence factors
S. aureus encodes 19,20. Shortly after the initial discovery of S. aureus, culture supernatants from
S. aureus isolates were observed to have toxic properties in animal models. Injections with the
supernatants were significantly injurious causing inflammation, dermonecrosis and lethality in
rabbit and guinea pig models 18,19,21. It was not until decades later that rigorous investigation into
S. aureus secreted proteins ensued, driven by a diphtheria vaccine incident in Bundaberg,
Australia in 1928 resulting in twenty-one ill children with ultimately twelve deaths. The onset of
illness was rapid and severe, within hours, 16 children suffered symptoms ranging from vomiting
to fever and convulsions, and within two days, 12 of the children had died. Furthermore, all of
the surviving children had abscesses at the site of immunization. Appointed by the
Commonwealth of Australia, F. McFarlane Burnet sought out to find the causative agent of this
tragedy. Burnet’s investigation revealed that the diphtheria vaccine preparation was
contaminated with S. aureus and concluded that substantial amounts of a toxic substance must
have been secreted from the bacterium. Burnet further observed that the vaccine-contaminating
strain as well as other S. aureus isolates all had the same multi-biological effects: hemolysis,
dermonecrosis upon intradermal injection and acute death when injected intravenously into
rabbits 18,19,21. Burnet and colleagues also demonstrated successful active and passive
immunization in naïve rabbits using formalin-treated S. aureus supernatants and serum collected
from immune rabbits, respectively. Active or passive immunity protected the naïve rabbits from
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lethal disease and also neutralized the hemolytic and necrotic activity of the S. aureus
supernatants.
Continuing studies in the 1940s eventually led to the identification of two distinct
secreted toxins, termed a and b toxin. Both a and b toxins had hemolytic capabilities leading
researchers to speculate that both toxins and potentially other secreted toxins may be responsible
for the toxicity from S. aureus supernatants 20,22. Toxin profiling studies by Glenny and Stevens
highlighted the differences between a and b toxins, demonstrating that the a-toxin had
hemolytic, necrotic and acute lethal properties among several species, phenocopying the S.
aureus supernatants. Another unique observation about a-toxin was the variation in hemolytic
susceptibility among species. For example, human erythrocytes were observed to be much less
sensitive to hemolysis, requiring a 400-fold-higher concentration of a-toxin to cause lysis as
compared to rabbit erythrocytes 19,20,21,22. Furthermore, rabbits had the lowest LD50 compared to
all other species tested at just 2 µg/kg of body weight, highlighting the unique sensitivity of
rabbit erythrocytes to the a-toxin 19,21.
Despite these significant findings across animal species, due to the relative insensitivity
of human erythrocytes, the importance of the a-toxin in human disease was highly debated for
decades. However, a notable study published in 1964 by Siegal and Cohen demonstrated that
platelet-rich human plasma treated with a-toxin induced morphological changes and aggregation
of platelets with subsequent procoagulant activity 19,21,23. Since this discovery, multiple human
cells have been shown to be susceptible to the toxin, including epithelial, endothelial and
hematopoietic-lineage cells. Furthermore, the toxin was shown to induce diverse responses
including spastic contraction in smooth muscle cells and liberation of lysosomal enzymes,
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shedding light on how this toxin causes injury and defining significant features of cellular
responses to intoxication 19,21.
Toxin classification
The notion that the a-toxin disrupts cell membranes through oligomerization and pore
formation was derived from studies in the 1970s through the 1980s. Toxin-treated liposomes and
nucleated cells treated with a-toxin leaked small molecules, corresponding to prior findings by
Siegal and Cohen that the a-toxin formed finite lesions on membranes 21,23. Furthermore, 10
nanometer ring-like structures with 6-7 subunits and a central pore of approximately 2-3
nanometers were visible by electron microscopy on cellular membranes when treated with high
concentrations of the toxin. Other functional studies demonstrated that molecules leaked from
toxin treated erythrocytes did not exceed 1-2 nanometers in diameter. These dimensions
corresponded to the channel structure observed by electron microscopy that extended through the
interior portion of the toxin oligomer 21,24. Around the same time, the complement complex
C5b-9 was also shown to form discrete lesions on cell membranes with visible ring-structures
and was soon identified as the first pore-forming cytolysin. Knowledge from these experiments
were applied to studies with the a-toxin where they were able to isolate the membrane-bound
ring structures, determining that they formed stable amphiphilic oligomers. In addition, early
studies using electron microscopy started to scratch the surface on the mechanism and function
of the toxin by concluding the following: 1) a-toxin had a strong binding interaction with target
membranes; 2) high concentrations formed 10 nanometer ring-like structures on cellular
membranes as well as liposomal membranes devoid of protein, and 3) binding seemingly caused
membrane damage and lysis 21.
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In the 1980s a conceptual model of the a-toxin pore-formation was devised and
hypothesized to be the primary mechanism of membrane damage. The model was as follows: the
a-toxin is secreted as a hydrophilic molecule and upon binding to target membranes,
oligomerizes to form a stable protein hexamer complex. The hexamer then undergoes a
conformational change, enabling the structure to insert into the target membrane generating a
hydrophilic channel across the lipid-bilayer forming a pore that disrupts membrane integrity 21,24.
Several studies thereafter confirmed this finding, and the a-toxin was the first identified poreforming bacterial toxin. The a-toxin became the prototype of b-barrel pore-forming toxins as
these studies helped identify several other proteinaceous toxins that damaged cell membranes in
a similar manner 21.
Toxin structure, function and regulation
Encoded in the core-genome of S. aureus by a single copy of the 960-bp hla gene, the atoxin is initially produced as a 319-residue precursor. The precursor includes a 26-residue ahelical signal peptide which is cleaved, and the a-toxin is then processed to yield a mature
secreted protein of 293 amino acids weighing 33.2 kDa 18,19,25,26. The toxin was initially thought
to aggregate to form a hexamer, however, in 1996 Song et. al solved the crystal structure of the
fully assembled pore, revealing the oligomer structure to be a heptamer, containing seven
protomer subunits 18,19,27. These studies tremendously advanced the knowledge and resolution of
the toxin structure as well as the functional model of toxin assembly. The mature toxin is
secreted as water-soluble monomers and upon binding to susceptible cells, seven monomeric
subunits oligomerize to form a 10-nanometer stable pre-pore heptamer. By an unknown
mechanism, each protomer from the pre-pore structure partially unfolds, creating a
transmembrane b-barrel which forms a 2-3 nanometer lytic pore 18,19,27,28,29. Interestingly,
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circular dichroism spectrum studies revealed that the mature toxin, including the
intramembranous domains that form the central pore, is predominantly composed of b-strands
with little to no α-helical structure 19,30. Furthermore, the crystallographic studies showed that the
fully assembled toxin resembles a mushroom-shape, 100Å wide by 100Å in height with an inner
pore diameter of 14Å 18,31. These studies also defined the three structural domains: (1) the
extracellular cap domain; (2) the C-terminal rim domain; and (3) the N-terminal stem domain.
The cap domain contains seven b sandwiches and the amino latch sequence (Ala1-Val20) of each
protomer, which make extensive interactions with the adjacent protomer, contributing to the
stability of the complex. The cap protrudes from the lipid bilayer surface, exposed to the aqueous
environment and shapes the entry of the pore. The rim domain has fewer protomer-protomer
interactions than the other domains but has direct contact with the lipid bilayer and projects from
the underside of the heptamer. The inner surface of the rim domain and the upper portion of the
stem domain, known as the rim–stem crevice, contain residues important for phosphocholine
binding to the cellular membrane. The stem domain forms the membrane-perforating b-barrel
pore, to which each protomer contributes two b-strands from a glycine-rich sequence, Lys100Tyr148, forming a continuous b-sheet. Once fully assembled, the hydrophobic residues are
positioned towards the lipid membrane and hydrophilic residues towards the lumen of the
channel 18,19,27,32.
Toxin expression is orchestrated by several global regulatory systems within the S.
aureus genome. Two-component systems and cytoplasmic regulators act as an interconnected
network to tightly regulate toxin expression, secretion as well as bacterial survival within the
host environment 18,19,33. The most important and best studied systems include the accessory gene
regulator (agr), the staphylococcal accessory protein effector (sae), and the staphylococcal
10

accessory gene regulator (sarA). The agr operon primarily controls toxin expression through a
peptide quorum-sensing system and the regulatory RNA molecule, RNAIII. During late log to
stationary phase of S. aureus growth, an accumulation of the secreted autoinducer peptide (AIP)
is sensed by the histidine kinase receptor, AgrC and activates the AgrC/AgrA two-component
system. AIP binding to AgrC, phosphorylates the receptor which in turn activates the
intracellular response regulator AgrA 19,33. AgrA then binds to the P3 promotor of the agr locus,
initiating the production of RNAIII, thus enabling toxin expression and secretion. Maximum
toxin production is reached during the stationary growth phase and rapidly secreted into the
environment, with only 1% remaining cell associated 19,33,34,35. Though this system primarily
regulates toxin expression, the two-component system, SaeR/S, and the cytoplasmic regulatory
system, SarA, fine-tune toxin expression through modulation of agr activity and simultaneously
coordinate responses to the changing host environment, ensuring optimal pathogen function and
survival 33,36,37.

1.3 Role of alpha-toxin in S. aureus Disease
While S. aureus has many virulence factors to promote disease, strains that have intact
and/or increased expression of a-toxin are hypervirulent compared to other strains. The first
cases of severe CA-MRSA infections in the U.S. were caused by isolates from the USA400
background. However, in the early 2000s, USA400 essentially disappeared and was replaced by
USA300 which was found to have increased virulence compared to USA400 and HA-MRSA
strains in a rat pneumonia model 18,38. Genome sequencing revealed that the major difference
between USA300 and less virulent strains was the expression of core global regulatory elements
agr and sae, which correlates to the amount of a-toxin produced 18,19,38. DeLeo et al showed that
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HA-MRSA isolates containing mutations in the agr locus, which resulted in a loss of a-toxin
expression, are less virulent in murine models of pneumonia and bacteremic infection 18,39.
Furthermore, Montgomery et al demonstrated that strains harboring a deletion of either the agr
or sae loci also results in complete loss of a-toxin expression with greatly reduced mortality in
murine pneumonia as well as the complete absence of dermonecrosis in skin infection 18,40.
These studies highlighted the significance of the global regulators in S. aureus pathogenesis,
however, PVL is another pore forming toxin important in pneumonia infection and also regulated
by agr and sae. Bubeck Wardenburg and others demonstrated that the a-toxin rather than PVL is
absolutely necessary for full virulence of S. aureus disease. Deletion of the hla locus eliminated
the ability of USA300 to cause lung infection, while deletion of the pvl locus did not affect the
overall mortality in S. aureus pneumonia. The same phenotype was also observed in several
other infection models such as skin, bloodstream, and corneal infections 18,41,42,43. Together, these
studies conclude that the critical factor for S. aureus pathogenesis is the presence of the a-toxin.
Experimental models and epidemiological data highlight the notion that increased a-toxin
expression is an advantage for the epidemic USA300 strain and because of this has the ability to
cause invasive infection in otherwise healthy individuals. In contrast, this genetic advantage is
not essential to cause infection in hospitalized patients likely due to an immunocompromised
state with underlying health conditions.

1.4 Discovery of the alpha-toxin receptor, ADAM10
Early studies theorized that the receptor for the a-toxin may be a lipid moiety stemming
from the observation that the toxin can bind and lyse protein-free membranes with a specific
composition of phospholipids 18,19,21,44,45. At high concentrations, the a-toxin can bind and lyse
12

liposomes composed of phosphatidylcholine or a combination of sphingomyelin and cholesterol.
Depletion of cholesterol or sphingomyelin on rabbit erythrocytes or susceptible cells abolishes
high-affinity toxin binding 18,19,46,47. Additional studies found that exogenous
phosphatidylcholine antagonizes toxin binding and thus reduces toxin-mediated hemolysis of
rabbit erythrocytes. Furthermore, phosphatidylcholine is also required for the function of other
staphylococcal pore-forming exotoxins, such as gamma-hemolysin and bicomponent leukocidins
18,32,48

. X-ray crystallographic studies with the heptamer and phosphatidylcholine provided even

more compelling evidence as it showed direct binding of the rim-stem crevice of the toxin and
phosphatidylcholine head groups, glycerophosphocholine and di-propanoyl phosphatidylcholine.
These studies also revealed two critical residues in the rim domain, W179 and R200, which have
side chains that protrude into the crevice, creating an attractive binding pocket for the
headgroups. These residues are also conserved in bicomponent leukocidins, suggesting a
structural requirement for pore-forming toxin binding and functionality on cellular
membranes18,32.
Though these studies provided key observations about the lipids necessary for toxin
binding and function, a proteinaceous receptor was still suspected due to the exquisite cell type
specificity and species specificity exerted by the a-toxin. The earliest and most drastic example
of differing susceptibility is between rabbit erythrocytes and human erythrocytes at low
nanomolar amounts of toxin can lyse rabbit erythrocytes, whereas micromolar concentrations are
required to lyse human erythrocytes 19,44. Other major observations that suggested a
proteinaceous receptor were: 1) treatment with pronase, a non-specific protease, reduces rabbit
erythrocyte sensitivity to a-toxin; 2) surface binding studies using radioiodinated a-toxin
estimated 1,200 – 5,000 binding sites per rabbit erythrocyte, making them 16,000 times more
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susceptible to hemolysis compared to human erythrocytes; 3) low concentrations of toxin
binding to rabbit erythrocytes was saturable, time and temperature dependent which are
characteristics indicative of a specific ligand-receptor interaction; and 4) treatment with high
concentrations of toxin on either rabbit or human erythrocytes was non-saturable and nontemperature dependent, indicating a non-specific nature of toxin binding 18,44,45,49. Together
these findings revealed two modes of toxin binding that supported the proteinaceous receptor
hypothesis and explained the lipid binding: where at low concentrations, the toxin utilizes a
proteinaceous receptor as a high affinity binding site and at high concentrations the toxin binds
non-specifically to lipid moieties on cellular membranes to facilitate binding and lytic function.
Moreover, these findings suggested that human erythrocytes may lack the high affinity binding
receptors and began to explain why certain cell types and species are more or less resistant to
toxin-mediated lysis due to varying expression of the proteinaceous receptor 44,45,49.
Initially, pore formation was thought to be the major source of a-toxin-induced injury to
the host, however, the discovery of the a-toxin proteinaceous receptor, ADAM10, uncovered a
dual mechanism which greatly advanced the knowledge of downstream pathologic effects of the
toxin-receptor interaction. In 2010, Wilke and Bubeck Wardenburg took advantage of the
species-specific receptor expression and purified the presumed a-toxin receptor using a
biochemical approach. A ~65kDa protein was isolated from rabbit erythrocyte membranes using
a non-toxigenic a-toxin mutant, GST-HlaH35L, which is capable of binding but devoid of pore
formation. This protein was unable to be recovered from human erythrocytes, consistent with
prior data demonstrating the lack of binding sites and cytotoxicity with toxin treatment. Mass
spectrometric analysis identified the isolated protein as ADAM10 (A Disintegrin and
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Metalloprotease 10), a zinc-dependent metalloprotease that is surface expressed on essentially all
cell types as a type I transmembrane protein.

1.5 Role of alpha-toxin and ADAM10 in S. aureus Disease
Further studies by Bubeck Wardenburg provided concrete evidence that ADAM10 was
likely the a-toxin receptor due to the downstream cellular effects of the Hla-ADAM10
interaction and its important role in S. aureus disease pathogenesis. First, they showed ADAM10
facilitates a-toxin binding to eukaryotic cells and ADAM10 expression is required for
cytotoxicity. This was demonstrated using a panel of human epithelial cell lines with varying
levels of ADAM10 expression showing a linear correlation between ADAM10 expression and
toxin binding. In addition, siRNA-mediated knockout of ADAM10 reduced toxin binding and
cytotoxicity. Second, a-toxin binding induced ADAM10 relocalization to caveolin-1-enriched
lipid rafts and subsequent barrier disruption via altered focal adhesion signaling. Caveolin-1 has
been previously shown to be important for toxin oligomerization, however, this data
demonstrated that the toxin requires both ADAM10 and membrane binding within caveolin-1enriched rafts. This toxin-receptor complex then utilizes the caveolin-1 platform to initiate the
clustering of signaling molecules and pore formation leading to the perturbation of cellular
barriers 18,45. As ADAM10 plays a role in multiple cellular homeostatic processes, tissue
development and immunologic function, these findings shed light on the hypothesis that the atoxin may alter normal ADAM10 activity 45,50,51. In addition, since a-toxin mediated injury is
dependent on the presence of ADAM10, this led to the hypothesis that animal models lacking
ADAM10 should be protected from the effects of the toxin in S. aureus disease.
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Over the last decade, Bubeck Wardenburg and colleagues developed several animal
models highlighting the role of ADAM10 in S. aureus disease pathogenesis and revealed an
unexpected mechanistic insight of a-toxin induced injury. Since ADAM10 is involved in various
developmental processes and tissue homeostasis, a global knockout of the Adam10 gene in mice
is embryonic lethal at E9.5 18,50,52. To circumvent this, in vivo studies utilized conditional or
inducible Adam10 knockout (Adam10-/-) mouse lines in various tissues such as epithelial
(alveolar and epidermal keratinocytes), endothelial, platelet and immune cells (myeloid lineage
and T cell). Bubeck Wardenburg showed mice harboring a conditional Adam10-/- in alveolar
epithelium or endothelial cells are largely protected from lethal pneumonia or bloodstream
infection compared to control mice 52, and Alfano, et al unpublished data. Similarly, epidermal
keratinocyte Adam10-/- mice challenged with subcutaneous infection resulted in smaller
abscesses as well as the absence of tissue dermonecrosis; a hallmark of a-toxin injury 42,52.
Interestingly, Adam10-/- on myeloid lineage or platelet cells revealed immunomodulatory effects
of the Hla-ADAM10 complex. Subcutaneous infection on myeloid lineage Adam10-/- mice
resulted in exacerbated skin lesions yet afforded protection against lethal pneumonia infection 53.
Furthermore, the loss of Adam10 on either platelet or myeloid lineage cells succumb to
bloodstream infection. However, Adam10 double-knockout mice harboring a myeloid lineage
Adam10-/- with either epithelial or platelet Adam10-/- are highly protected against S. aureus
infection 54.
Further investigation into the molecular mechanisms of the toxin-receptor interaction
uncovered a unique characteristic of the a-toxin. At sub-lytic concentrations, the toxin pore
causes rapid upregulation of ADAM10 metalloprotease activity resulting in the pathologic
cleavage of native ADAM10 substrates 52. For example, in skin, lung and bloodstream infection,
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barrier disruption and subsequent disease progression is associated with the pathologic cleavage
of adherens junctional proteins, E-cadherin and VE-cadherin induced by a-toxin. Furthermore,
these animal models uncovered the systemic effects of immunomodulation and altered cytokine
and chemokine signaling induced by the a-toxin. While myeloid cells such as neutrophils and
macrophages are more resistant to the lytic action of the a-toxin due to the intrinsic low level of
surface expression of ADAM10, exposure to a-toxin dampens their ability to produce IL-1ß.
This dampened response intensifies the epidermal tissue damage seen in myeloid lineage
Adam10-/- mice in skin infection yet provides protection against pneumonia infection since a
proinflammatory state contributes to lung injury 53. Another important insight from the platelet
and myeloid Adam10-/- mice showed that the Hla-ADAM10 interaction effects the immune
response by altering platelet activation and promotes neutrophil inflammatory signaling.
Moreover, a-toxin not only damages platelets which prevents endothelial barrier repair, but also
facilitates formation of injurious platelet-neutrophil aggregates, contributing to lung and liver
injury. Further supporting the direct role of ADAM10 in S. aureus infection, an ADAM10
specific inhibitor blocks cadherin proteolysis, preserving the tissue barriers and significantly
attenuating pneumonia and sepsis lethality and dermonecrosis in skin abscesses 41,42,52.
These studies provided several valuable insights not only for S. aureus pathogenesis but
also for pore-forming toxin biology in general as this was the first time a b-barrel pore-forming
toxin was shown to interact with a receptor in this way. Moreover, these studies explained the
remarkable ability of a single bacterial toxin to coordinate progressive disease through tissue
specificity and modulation of host immunity.
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Chapter 2
alpha-toxin and ADAM10 Binding Interaction
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2.2 Important Residues in Toxin Binding and Oligomerization
Structure-function analysis of a-toxin through scanning mutagenesis has revealed key
residues for toxin binding and function. Residues R66, E70, W179, R200, D254 and D276 located in
the rim and b-sandwich and are required for toxin membrane binding. Cysteine mutants of these
residues maintain full toxin assembly; however, the lytic function is greatly reduced due to the
cellular binding defect 32,57. Furthermore, mutations at residues D24, K110 and D152 retain
membrane binding but impact pore-formation as they are arrested in the oligomer pre-pore, thus
disabling the lytic function of the toxin pore. Interestingly, the N-terminal segment known as the
amino latch undergoes a conformational shift, latching onto the neighboring protomer which
stabilizes the toxin oligomer 55,57. Within the N-terminal segment, H35 is a critical residue located
at the interface between protomers and aids in the stabilization and pre-pore to pore transition.
During toxin assembly, H35 moves into a hydrophobic environment initiating the insertion of the
stem domain into the membrane. Mutations at this position retain membrane binding yet renders
a completely inactive toxin as the interprotomer connections are destabilized and therefore
unable to fully assemble into the pore 55,56,57,58.
Examining the pore-forming mechanism in more detail remained a challenge for years as
only the fully assembled toxin crystal structure was available. However, in 2015 Sugawara et. al
generated crystal structures using a double mutant (W179A/R200A) and a single mutant (H35A)
that allowed the toxin to be visualized in the soluble monomeric and pre-pore structures,
respectively 58. Structure comparison of the monomeric, pre-pore and fully assembled crystal
structures uncovered a dynamic pore-formation mechanism. First, the pre-stem in monomeric
form is secured to the cap domain by a key hydrogen bond between residues D45 and Y118. Next,
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as the pore assembles, hydrophobic interactions between the cap domain and the N-terminal
amino latch of the adjacent protomers play a key role. The N-terminal amino latch folds into a
short helix, creating a hydrophobic core with residues of the adjacent protomer, stabilizing the
extended amino latch within the pore state. Simultaneously, this conformational shift destroys
the key hydrogen bond between D45 and Y118, allowing the pre-stem to be released and fold down
into the pore. Lastly, the release of the pre-stem exposes the hydrophobic surface on the cap
domain which binds the amino latch of the adjacent protomer, further stabilizing the pore. Of
note, two hydrophobic residues I5 and I7 important in the structure of the amino latch, also aid in
the conversion of the amino latch from monomer to oligomer. These analyses also showed that
the toxin pore is formed in a two-step process where the extracellular b-barrel is formed in the
pre-pore state, and the transmembrane region inserts into the membrane to form the pore, which
completes the pore formation. This mechanism is consistent with other two-component
staphylococcal pore-forming toxins 58.

2.2 ADAM10 structure and domains
ADAM10 belongs to the ADAM family of zinc-dependent metalloproteases found in all
vertebrate tissues and involved in several processes from fertilization and neurogenesis to wound
healing and inflammation 51. These proteins have many important regulatory functions and act as
an ectodomain sheddase, releasing a variety of cell-surface proteins such as growth factors,
cytokines, cell adhesion molecules and receptors as well as cleave and remodel extracellular
matrix components. Additionally, the release of the soluble portions of the ectodomains can
influence intracellular cell signaling pathways. Due to the overall critical role of ADAMs,
dysfunction of these proteins is implicated in a wide range of diseases including rheumatoid

20

arthritis, Crohn’s disease, diabetes, Alzheimer’s, cardiac hypertrophy, cancer and microbial
infections 51,59,60,61.
Zinc metalloproteases are divided into subgroups based on the primary structure of their
catalytic site and further divided by the domains they contain 62. A distinguishing feature of the
ADAM subgroup is the presence of a disintegrin domain and a conserved methionine b-loop
structure near the zinc-binding motif, a key characteristic of the metzincin superfamily of zinc
metalloproteases 62,63,64. ADAMs are single membrane spanning proteins that share a common
modular structure. ADAM10 and its closest homologue, ADAM17, have a transmembrane
domain that connects to a C-terminal cytoplasmic tail and three ectodomains containing an Nterminal signal sequence preceding a prodomain, followed by a metalloprotease, a disintegrin
and a cysteine-rich domain 51,61. Furthermore, these proteins are synthesized as zymogens, where
the immature form of the protein contains an N-terminal prodomain that gets removed during
processing, converting the inactive precursor into a mature active protease upon surface
expression 64.
ADAM10 domain function
The N-terminal signal sequence directs ADAMs to the secretory pathway and the
prodomain keeps the metalloprotease domain inactive through a conserved cysteine residue that
acts as a cysteine switch. This switch within the prodomain sequesters the required active site
zinc ion, ultimately preventing the metalloprotease activity. The prodomain also acts as a
chaperone, aiding in the proper folding and maturation of ADAMs. The metalloprotease domain
engenders the ectodomain sheddase function through zinc and water ions necessary for the
hydrolytic processing of protein substrates. The active site consensus sequence contains three

21

conserved histidine residues (HExxHxxGxxH) and a downstream methionine that lies within the
'met turn motif' that faces the active site. The disintegrin domain is a distinguishing feature of the
ADAM proteins and mediates cell-cell adhesion 60,62,65. Furthermore, this domain interacts with
integrins and was first discovered in snake venom as they disrupted specific platelet integrins and
inhibit platelet aggregation. The cysteine-rich domain works together with the disintegrin domain
to facilitate extracellular protein interactions and are both involved in the regulation of catalytic
activity, substrate targeting and recognition and removal of the prodomain60,65,66,67. Furthermore,
the surface exposed residues in these domains are highly divergent among the ADAMs which is
consistent with the various substrate profiles of the ADAM family members 60,66. The
transmembrane domain passes through the lipid bilayer one time and connects the ectodomains
to the C-terminal cytoplasmic tail. The cytoplasmic tail has been suggested to aid in several
signaling events including the inside-out regulation of the metalloprotease activity, the outside-in
regulation of cellular signaling, and the control of maturation and subcellular localization.
Furthermore, this domain also has potential phosphorylation sites for serine-threonine and/or
tyrosine kinases that may influence maturation, activity and intracellular transport 60,62.

2.3 Hla-ADAM10 Binding and The Role of ADAM10 Activity in Disease
While ADAM10 metalloprotease activity has been shown to be upregulated in several S.
aureus disease models, it was unclear if toxin pore-formation and ADAM10 activation were both
required to mediate disease pathogenesis. Furthermore, the toxin-receptor interaction interface
remained elusive as the toxin does not bind to purified ADAM10, likely due to the requirement
of the receptor to be in a specific conformation as it is within the cellular membrane. Recent
structure-function analysis data of the Hla-ADAM10 complex from the Bubeck Wardenburg lab
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revealed that the metalloprotease domain is necessary for Hla binding and cytotoxicity.
Moreover, a limited stretch of residues conserved across species in ADAM10 mediate this
interaction, providing molecular insight on toxin specificity of receptor utilization. Interestingly,
in vitro and in vivo analysis of a catalytically inactive ADAM10 mutant harboring a point
mutation in the active site (ADAM10E384A) revealed that ADAM10 enzymatic activity is not
required for Hla binding but remains essential for cytopathic effects on lung epithelial cells in
vitro, as well as pathogenesis in a lethal mouse model of S. aureus pneumonia and sepsis. While
transgenic mice expressing wild-type bovine ADAM10 succumbed to infection, mice expressing
the catalytically inactive bovine ADAM10E384A were equally recalcitrant to S. aureus pneumonia
and sepsis as ADAM10 knock-out mice, illustrating the exquisite biological coupling of toxin
pore formation and ADAM10 metalloprotease activity in pathogenesis (Tomaszewski and
Berube unpublished data, Alfano unpublished data).
Due to the complexity and instability of ADAM10 as a transmembrane protein, the
crystal structure of this protein is only partially solved, leaving structural and mechanistic
questions open and only predicted. However, recent studies by Seegar et al. determined the
ectodomain crystal structure which provided valuable insight into the regulation of ADAM10
activity, which may be important for toxin binding and function. They proposed a model of
ADAM10 activation where ADAM10 switches between an ‘open’ and ‘closed’ confirmation for
substrate accessibility 61. In the closed confirmation, the cysteine-rich domain partially occludes
the active site on the metalloprotease domain rendering ADAM10 inactive. In addition, they
identified an ADAM10 antibody, which, upon binding, alters the shape of the ADAM10 protein,
causing the displacement of the cysteine-rich domain from the active site and upregulation of
ADAM10 metalloprotease activity.
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These findings along with the binding and catalytic activity data led us to two key
hypotheses: 1) The activity state and structural conformation of ADAM10 may differentially
influence Hla binding and function and 2) the tertiary structure of Hla and how that effects the
interaction with ADAM10 may be an important implication in the immune response and disease
outcome. In the closed confirmation, the cysteine-rich domain partially occludes the active site
on the metalloprotease domain which may impede toxin binding. Furthermore, previous studies
using a small molecule inhibitor of the active site precludes Hla-ADAM binding 41, further
supporting this idea. Identifying the exact mechanism and structural interface between the toxin
and receptor could provide greater insight into the biologic function of pore-forming toxins in
general. In addition, whether the toxin can interact with ADAM10 or not, may influence
different immune pathways that shape the disease outcome and subsequent immunity.
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Chapter 3

Structural analysis and vaccine efficacy of Hla mutants
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3.1 Introduction
Past vaccine clinical trials
While anti-bacterial vaccines have significantly mitigated other diseases such as B. pertussis, C.
diphtheriae, C. tetani, and S. pneumoniae, generating a successful S. aureus vaccine has
remained a major challenge in the field. In the last two decades, a substantial amount of effort
has been focused on S. aureus vaccine development generating 16 candidate preparations;
however, none were proven to be successful in clinical trials 68,69,70. In fact, 10 out of the 16
candidate immunization strategies failed human clinical trials, including three high-profile Phase
3 active vaccine candidates. Furthermore, the remaining vaccine candidates are either at a standstill with no further development after trial completion or studies are ongoing without any reports
on the data outcome 10,12,69. Nonetheless, these failed efforts have provided researchers with
insight into the immunization design flaws and unique challenges of S. aureus.
The fact that S. aureus is a commensal of the skin and has evolved with humans allows
this pathogen to remain as a persistent or intermittent colonizer, creating a baseline 'host
tolerance' which is uncommon compared to other pathogens. Furthermore, most adult humans
have high antibody titers against several staphylococcal antigens, however, these antibodies do
not provide significant protection against S. aureus infection 70. Recent studies by the Bubeck
Wardenburg lab showed that S. aureus skin infection causes a defect in adaptative immunity,
specifically the T cell response and loss of dendritic cells due to the a-toxin (Hla). In addition,
Hla exposure caused more than a 2-fold reduction in the number of antigen-specific CD4+ T cells
that respond to S. aureus infection, while toxin neutralization through active or passive immunity
restores T cell development 71. These studies led to the hypothesis that early exposure to S.
26

aureus and a-toxin causes an ‘original antigenic sin’ phenomenon in which subsequent
exposures only amplifies the initial non-protective immune response, leaving the host susceptible
to disease. This phenomenon has been described in other pathogens such as influenza, SARSCoV-2, dengue fever and HIV where reinfection is common and/or the immune response is
defective due to a dominant antigen from initial infection perpetuating the flawed immune
response to succeeding infections 72-76.

3.2 Vaccine Candidate Design and Hla-ADAM10 Mouse Model
Since most of the population is exposed to the a-toxin early in life - either through
commensal colonization or S. aureus infection; one potential explanation for the clinical trial
failures is that all immunization strategies have been tested in adults. In fact, these adults all
harbored evidence of pre-exposure to the a-toxin where their immune system has already been
primed and programmed with a potentially unfavorable immune response. In addition, multiple
S. aureus virulence factors have been tested, however, Hla is perhaps one of the most influential
virulence factors S. aureus encompasses and has been previously demonstrated to be an effective
immunogen early upon its discovery 21. Solely targeting Hla through passive and active
immunization has also been proven to be effective against S. aureus disease in multiple preclinical studies from Bubeck Wardenburg and others 77-82.
Due to the tremendous amount of evidence on the deleterious effects of the a-toxin in S.
aureus disease and the role of the Hla-ADAM10 complex that we have previously described; we
propose a two-fold strategy for a novel S. aureus vaccination design: Strategy 1) neonate
vaccination aimed to neutralize Hla will improve the adaptative immune response by allowing a
more diverse T-cell repertoire to be generated and therefore provide long-lasting and effective
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protection against subsequent insults later in life; Strategy 2) the Hla and ADAM interaction is
important to consider in the design of vaccine candidates as Hla mutants that disrupt or preserve
this interaction may be key in mounting a more effective immune response.
We sought to test the hypotheses from Strategy 2 by immunizing mice with Hla mutants
that would alter or preserve the binding efficiency to ADAM10 as well as change the tertiary
structure of the toxin. The three candidate vaccinations include a single substitution mutant
H35L, and two double mutants D45A/Y118F and R66C/E70C. Residue H35 is located at the
protomer-protomer interface of each monomer within the cap domain and is critical for the
stabilization of the oligomeric structure. Substitution of the histidine residue to leucine
destabilizes the oligomeric structure, thus abolishing toxin activity and is not predicted to alter
the structure of the monomer. Furthermore, this mutation has also been shown to maintain
binding to ADAM10 comparable to wild-type toxin 45,52. A key hydrogen bond between residues
D45 located in the cap domain and Y118 located in the glycine-rich loop keep the pre-stem intact
with the cap domain before the pre-pore to pore transition. Substitutions at these residues is
predicted to disengage the pre-stem from the cap domain and considerably alter the monomeric
and tertiary structure as well as expose the amino latch. Residues R66 and E70 reside in the rim
domain and have been previously demonstrated to be important for membrane binding.
Substitution of these residues should alter the toxin binding properties, therefore diminishing the
Hla-ADAM10 interaction but maintain a normal toxin structure.
In addition to these studies, we generated a mouse model as a tool to visualize the HlaADAM10 interaction. Visualizing the binding interface as well as the conformation of these
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proteins will allow us to gain structural insight into the complex molecular actions that conclude
with toxin pore formation and ADAM10 activation.

3.2.1

Figure 3.2.1 Hla mutant schematic
Crystal structures of monomeric alpha-toxin (left) and fully assembled heptameric alpha toxin
(right). Residue H35 is colored lavender and located in the mid cap domain (light gray), residues
D45 and Y118 are colored blue located in the upper cap and stem domains (light gray and dark
gray) respectively, and residues R66 and E70 are colored orange and located in the rim domain
(medium gray).
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3.3 Results
3.3.1 Characterization of mutant Hla variants: rRBC Lysis
To assess the effect of mutations on the activity of the toxin, rabbit RBCs were incubated
with a range of purified toxins (Supp. Fig. 3.7.1) and the capacity to lyse rabbit RBCs following
incubation was determined. Absorbance of lysate at 450nm was measured and used to determine
percent lysis (Fig. 3.3.1A) Mutant H35L is completely inactive at all concentrations, as expected
from prior literature, while D45A/Y118F and R66C/E70C maintained some ability to lyse cells
at high concentrations. At 10 µg/mL, D45A/Y118F has no detectable lysis, however,
concentrations above this restores lytic ability though significantly reduced compared to wild
type or R66C/E70C (data not shown). R66C/E70C is significantly more active than
D45A/Y118F as rabbit RBCs treated with this mutant results in over 80% lysis at 10 µg/mL.
However, R66C/E70C is less active than wild type as it loses the ability to lyse as the toxin is
diluted but still results in over 50% lysis at the second dilution of toxin (5 µg/mL). Toxin activity
is not detectable beyond the 4th serial dilution (1.25 µg/mL). Due to the fact that both double
mutants maintain residual toxin activity, we generated triple mutants to include H35L
(H35L/D45A/Y118F, H35L/R66C/E70C) for examination as potential vaccine candidates. We
then repeated the RBC lysis assay to ensure the vaccine candidate mutants were completely
detoxified as seen with the H35L single mutant. As shown in Fig. 3.3.1B, both triple mutants
have no detectable lysis at all concentrations, making these suitable antigens for vaccine
analysis.
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3.2.2 Characterization of mutant Hla variants: Binding and Oligomerization
Capacity
To evaluate the ability of mutant toxins to interact with host cells, in vitro translated 35S
radiolabeled Hla mutants were generated (Supp Fig. 3.7.2) and used to evaluate the effect of the
mutations on toxin binding to rabbit RBCs. All mutants generated an appropriate amount of
protein and were radiolabeled efficiently. Of note, the D45A/Y118F mutation did cause the toxin
to spontaneously oligomerize as shown by the high molecular weight band at ~175 kDa. To
ensure the same amount of radiolabeled monomeric toxin was used in each assay, the band
intensity of the monomer was calculated and normalized to wild type monomer. Rabbit RBCs
were incubated with [35S] labeled toxin at room temperature for 5 minutes, washed and then the
cellular fraction was resuspended in scintillation fluid and bound 35S-toxin was read on a liquid
scintillation counter. As expected, there was no difference in binding capability with the single
H35L mutation compared to wild-type, however both triple mutants significantly reduced the
ability of Hla to bind to rabbit RBCs with H35L/R66C/E70C having the most prominent
reduction (Fig 3.3.2A). In addition, we tested the double mutants (D45A/Y118F and R66CE70C)
without the H35L mutation and as expected this did not change the binding efficiency of either
mutant (data not shown).
The ability of Hla mutant toxins to assemble into pores and the stability of the pores
formed was also interrogated. To analyze mutant toxin oligomerization, 35S radiolabeled mutant
toxins were incubated with rabbit RBCs for one hour at room temperature followed by exposure
to 37°C, 60°C, or 80°C. Samples were analyzed by SDS-PAGE and phosphorimaging. The
presence of high molecular weight oligomers is indicative of pre-pore/pore formation on the
rabbit RBC surface. An oligomer complex was detected for all mutant toxins, however, the band
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intensity for the triple mutants was significantly reduced due to the overall binding defect ensued
with these mutations (Fig. 3.3.2A, B). Previous studies have demonstrated that wild type toxin is
SDS and heat stable up to 66°C, while mutations that disrupt oligomer stability have a reduced
capacity to remain in the assembled pre-pore at 50°C 77. As expected, all mutants have detectable
~33kDa monomeric bands (denoted by the arrow) at each temperature and ~175kDa oligomer
bands at 37°C (denoted by Hla7), while these bands are lost at 80°C (Fig. 2B). H35L has been
previously demonstrated to lose oligomer stability above 50°C, however, all mutant oligomer
complexes including H35L, were present at 60°C. This result for H35L is likely due to the high
concentration of toxin used in this assay to accommodate for the significant loss of binding
signal with the other mutants. Since the double mutants retain some ability to lyse cells, while
H35L does not, suggests that these mutations do not appear to completely abolish the stability of
the oligomer or pore formation.

3.3.3 Impact of mutants on Hla structure and stability
In collaboration with the Amarasinghe lab, we examined the structural stability of each
mutant using a thermal shift assay (TSA). In brief, this assay measures the melting temperature
of a protein, defined by the temperature at which there is 50% protein denaturation, thus
hydrophobic residue exposure. This assay utilizes ThermoFluor SYPRO Orange dye which binds
nonspecifically to hydrophobic residues and is quenched by water. As the temperature increases,
proteins will become disordered, exposing hydrophobic residues, which results in an increase of
SYPRO Orange binding and fluorescence 83,84. As shown in Figure 3.3.3, wild-type Hla, H35L
and H35L/R66C/E70C exhibit similar melting curves, reaching 50% denaturation at 61-63°C. In
contrast, H35L/D45A/Y118F does not reach 50% denaturation until almost 80°C, however the
dye is able to bind before the protein has been exposed to an increase in temperature. This data
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suggests that the monomeric structures of H35L and H35L/R66C/E70C are not altered and
remain compact or globular in overall structure, comparable to the wild-type toxin.
H35L/D45A/Y118F appears to be more stable than the other proteins, however, dye binding at
room temperature indicates that the structure is inherently more disordered. This finding is wellaligned with our prediction that D45A and Y118F mutations disengage the pre-stem from the cap
domain, thereby exposing the hydrophobic surface on the cap domain in the monomeric form.

3.3.4 Antigens and adjuvants have differential protection against S. aureus skin
infection
To address if these distinct antigen properties and interaction with ADAM10 influence
the immune response and adjuvanticity, we utilized two different FDA-approved adjuvant
formulations with each toxoid and immunized mice prior to S. aureus skin infection. The first
adjuvant contains squalene/DL-a-tocopherol/polysorbate 80 (AS03-like) and the second contains
alum/monophosphoryl lipid A (AS04-like), both of which have been demonstrated to increase
the number of activated CD11c+ dendritic cells in the draining lymph node which are the main
driver of antigen-specific T-cell priming 85. As seen in Figure 3.3.4, all vaccine candidates with
both adjuvant formulations provide significant protection against S. aureus skin infection
compared to the sham controls. However, the vaccine candidates formulated with the AS03-like
adjuvant were overall more effective and significantly reduced the abscess and dermonecrosis
lesions compared to the AS04-like formulation. Of the vaccine antigen candidates, mice
immunized with H35L/D45A/Y118F exhibited the largest lesions in both formulations with the
most prominent difference within the first 48 hours post-infection. In fact, the abscesses were
over two-fold larger in the AS04-like formulation compared to the AS03-like formulation. This
reduction in protection was also evident in the dermonecrotic lesions in the AS04-like
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H35L/D45A/Y118F-immunized mice with almost a 2-fold increase in lesion size compared to
the other vaccine candidates.

3.3.5 Analysis of antibody titers and neutralizing capability
Anti-Hla serum antibody EC50 titers from vaccinated mice indicated successful
vaccination as all vaccine candidates with both adjuvant formulations had a significant increase
in antibody response above adjuvant control. Of the serum antibody responses, toxoids in
combination with the AS03-like formulation all generated higher antibody titers compared to
toxoids in combination with the AS04-like formulation, with H35L/R66C/E70C reaching
significance (Fig. 3.3.5A). Interestingly, H35L/R66C/E70C generated the most robust antibody
response in the AS03-like formulation with about a 2-fold increase in antibody titer as compared
to the other vaccine candidates. Serum collected from the vaccinated mice was also tested for
Hla neutralizing capacity. Rabbit RBCs were incubated with serum for 1 hour and then treated
with wild type toxin. H35L/R66C/E70C exhibited a remarkable toxin neutralizing capability as
compared to the other vaccine candidates providing 50% protection at dilution 1:3200 (Fig.
3.3.5B). The neutralizing capacity was not as prominent in the AS04-like formulations, but the
overall trend remained the same. Figure 3.3.5C shows a plot of serologic protection from Hlainduced rabbit red cell lysis as a function of anti-Hla serum EC50 titer from vaccinated mice.
Though the AS03-like formulations with H35L and H35L/D45AY118F generated similar
antibody titers, the neutralizing capacity was greatly reduced with H35L/D45A/Y118F as RBC
lysis reaches nearly 50%. In contrast, H35L/R66C/E70C had nearly a two-fold higher EC50
antibody titer than H35L however these antigens provided similar neutralizing capacity in both
formulations. The diminished antibody titer and neutralizing capacity was even more evident
with AS04-like adjuvant in combination with H35L/D45A/Y118F resulting in 70% RBC lysis.
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These plots highlight key differences in the antigen/adjuvant formulations on overall vaccine
effectiveness.

3.3.6 VavCre+/- bAdam10+ red blood cells are sensitized to Hla
The details of the toxin-receptor interaction interface have remained elusive as purified
ADAM10 is unable to bind the toxin, likely related to a requirement for receptor conformational
determinants that only exist when displayed in the host cell membrane. To address this biological
challenge, we generated a transgenic mouse line with increased Adam10 expression on the
surface of red blood cells. We utilized an established mouse line that harbors a bovine Adam10
transgene driven under a CAG promoter and crossed them to mice containing the cre
recombinase under control of the mouse vav 1 oncogene (Vav1) promoter which results in
hematopoietic expression of the downstream gene. Upon tissue specific Cre-mediated
recombination, endogenous Adam10 is knocked out and bovine Adam10 (bADAM10) is
expressed only in hematopoietic and progenitor cells (Fig. 3.3.6A). As murine red blood cells
natively have low surface expression of ADAM10, it was unclear if it would be possible to
generate an ADAM10 knock-in model on this cell type. To examine this, red blood cells were
isolated from VavCre+/- bAdam10+ and control (VavCre negative) mice and treated with purified
toxin. As shown in Figure 3.3.6B, red blood cells isolated from VavCre+/- bAdam10+ mice were
significantly more sensitive to toxin treatment as compared to red cells isolated from control
mice. In addition, VavCre+/- bAdam10+ red blood cells also showed a significant increase in
toxin binding (Fig. 3.3.6C). This data demonstrates that mouse red blood cells can in fact express
an increased amount of functional ADAM10 on their surface. Furthermore, this data confirms
the membranes of VavCre+/- bAdam10+ expressing red blood cells can be used to visualize the
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Hla-ADAM10 complex in its native confirmation with techniques such as cryo-electron
microscopy.

3.4 Discussion & Conclusion
The a-toxin or Hla has long been recognized as one of the most important virulence
factors encoded by S. aureus as it plays a critical role in injury in both skin necrosis and lethal
infections. Though S. aureus and a-toxin have accumulated nearly a century’s-worth of valuable
research, major challenges that have hindered the field include: 1) the exact mechanism of the
transformation from the oligomeric structure into the pore remains elusive; 2) the complete toxin
and receptor binding interface and confirmational determinants are unknown; 3) no vaccine
strategy against multiple virulence factors, including the a-toxin, has been successful.
Recent data from our lab has provided valuable insight on the first two challenges. We
have shown specific regions within the metalloprotease domain proximal to the active site as
well as the catalytic activity of ADAM10 are necessary for toxin binding and function.
Furthermore, recent studies by Seegar et al., demonstrated that the cysteine-rich domain partially
occludes the active site within the metalloprotease domain when ADAM10 is in an inactive state.
Based on these findings we hypothesized that the structural confirmation and the activity state of
ADAM10 may influence toxin binding. It is tempting to speculate that Hla binding to the
metalloprotease domain could alter the ADAM10 structure enough to displace the cysteine-rich
domain, and thus trigger the ADAM10 sheddase activity characteristic of Hla intoxication.
The fact that purified ADAM10 and Hla do not interact in solution has made studying
this interaction challenging. Recent identification of host receptors for several bacterial toxins
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has proven the necessity of live cells for proper folding of the receptor in its native lipid
environment 86. In order to better understand the Hla and ADAM10 interaction, we proposed to
use red blood cells as they are an attractive cell model to use for a few reasons. First, RBCs are
simple cells with a well-defined surface protein profile. The use of red blood cells will thus
provide the lipid membrane needed for native protein folding as well as make visualization of the
Hla-ADAM10 complex more targeted. Furthermore, we can generate RBC ghosts where the
cellular membrane is preserved but devoid of other cellular components such as hemoglobin, etc.
Second, RBCs are less sensitive to Hla-mediated lysis due to the low surface expression of
ADAM10. This allowed us to easily assess if the transgene knock-in system is viable in these
cells. The increase in Hla binding with VavCre+/- bAdam10+ RBCs compared to control RBCs
demonstrated the transgene cassette expressed an increased amount of ADAM10 as expected
(Fig 3.3.6B). In addition, we were also able to show this system is functional as RBCs with
bAdam10 expression are sensitized to Hla-mediated lysis (Figure 3.3.6B). Last, isolating RBCs
from mice is relatively simple and does not require terminal procedures. Submandibular bleeds
can be performed on consecutive days and provides plenty of cells to use in multiple assays.
We therefore predict that this cell model can be used for advanced microscopy
techniques which will allow us to gain structural insight into the complex molecular actions that
conclude with toxin pore formation and ADAM10 activation. Cryogenic electron microscopy
(CryoEM) and cryoelectron tomography (CryoET) provide the capability of high-resolution
imaging of the molecular dynamics of proteins and protein complexes. In fact, recent advances in
hardware and software cryo microscopy technology allows for a larger range of molecular
weights and imaging at molecular to near-atomic levels as well as more flexible sample
conditions 87,88. Briefly, both techniques take thousands of 2D images at all possible
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perspectives of the sample in a frozen-hydrated state, which captures how it naturally exists in
solution. These images then get compiled into a 3D model. CryoEM captures images of many
different parts of the structure that are frozen in various orientations (face-up, face-down, tilted
to the side, etc.) while CryoET captures sequential pictures of a single structure as it is slowly
rotated or tilted along one axis. CryoET can also resolve ambiguity present in 2D projection
images and is better suited to image single and/or flexible structures that are difficult to visualize
with CryoEM 87,88. Utilizing both techniques will provide unique insight to the Hla and
ADAM10 complex as we will be able to visualize basic uniform structures and
heterogenous/flexible components of the structures when they interact. Some challenges and
limitations to these techniques include a significant amount of sample optimization and the
number of images that can be taken at one time to preserve sample integrity. Managing beam
dosage will be important especially when using CryoET since a single particle will be constantly
exposed and can only tolerate a low electron dose before significant damage occurs to the
structure.
The third major challenge hindering the field has been the development of a successful S.
aureus vaccine. It has already been established in multiple preclinical studies that active
vaccination targeting Hla provides protection against infection 77-82. However, due to the critical
role of the Hla-ADAM10 interaction in S. aureus disease, we wondered if this interaction
influences immunogenicity. The vaccine candidates we evaluated were chosen based on
mutations that would not only alter the Hla-ADAM10 interaction but also the tertiary structure of
Hla. H35L is a well characterized detoxified mutant and has been previously used in vaccination
studies with great success in various mouse models 78. Furthermore, this mutation is not
predicted to change the tertiary structure and does not interfere with the Hla-ADAM10 binding
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interaction (Figure 3.3.2A). To create an opposite effect, we generated the D45A/Y118F and
R66C/E70C variants. D45A/Y118F is predicted to significantly change the tertiary structure by
disengaging the pre-stem from the cap domain. In theory this would expose the N-terminal
amino latch as well as partially unfold the monomeric structure. R66C/E70C is predicted to
affect the binding properties, therefore preventing the Hla-ADAM10 interaction which would
keep the toxin soluble.
Before we could analyze these vaccine candidates in vivo, we needed to ensure these
mutations would detoxify the proteins to be safely used as vaccine antigens. We utilized rabbit
red blood cells as they are the most sensitive cell type to the toxin and classically used to
determine hemolytic activity of the a-toxin. During our initial characterization of these mutants,
we found that both D45A/Y118F and R66C/E70C retained some lytic ability at 10 µg/mL or
higher concentrations. This is not surprising for variant R66C/E70C as the mutations located in
the rim domain have not been demonstrated to impact oligomer or pore stability 32,57. We were
unsure if the pre-stem detached from the cap domain would affect the oligomer or pore stability,
however, D45A/Y118F did retain some lytic ability at higher concentrations than 10 µg/mL
(data not shown). In addition, both variants ensued significant binding defects compared to wildtype and H35L, with R66C/E70C having the most prominent defect, as expected. Though the
binding efficiency was reduced, both variants still appeared to form oligomeric complexes on
rabbit red blood cells. The fact that these mutants still retain some hemolytic activity and H35L
does not, suggests that the oligomeric complexes in these variants are stable and therefore
undergo pore formation. The binding defect seems to be the main driver for reduced hemolytic
activity in R66C/E70C, however, since D45A/Y118F has an intermediate binding capability and
the hemolytic activity is even more reduced, suggests that the oligomer complex may be less
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stable with D45A and Y118F mutations. These results are consistent with the non-specific
binding ability of the toxin at high concentrations. This is nicely demonstrated with the
R66C/E70C variant as it significantly loses lytic activity as the toxin is serially diluted. Due to
the above findings, we finalized the vaccine candidates to have H35L as a third mutation to
completely inactive them without changing the structure or binding properties. As shown in
Figure 3.3.2B, introducing H35L into these variants completed inactivated the toxins without
affecting binding (double mutant compared to triple mutant binding data not shown).
Next, we examined the effects of these mutations on the stability and structure of the
proteins in solution. Thermal shift assays measure the thermal denaturation profile of proteins,
indicating at which conditions and temperatures proteins are less tightly folded. This
methodology is classically used to analyze protein stability within different solutions as well as
protein-ligand interactions 84. One of our rationales for novel vaccine design is that the structure
of the antigen may influence immunogenicity and/or adjuvanticity. Moreover, altering the ability
of the toxin antigen to interact with the host receptor may also drive a different immune
response. Both H35L and H35L/R66C/E70C mutations seem to preserve the native monomeric
structure of the toxin as well have a similar denaturing profile. Interestingly, H35L/D45A/Y118F
showed increased binding of the SYPRO Orange dye at room temperature, indicating the
monomeric structure is very different from the wild type and other mutants. In addition,
H35L/D45A/Y118F did not reach 50% denaturation until almost 80°C. Together, this data
suggests that the D45A/Y118F mutations do in fact disengage the pre-stem, exposing
hydrophobic residues and significantly changing the structure, while H35L and R66C/E70C
mutations do not have an overall effect on the structure of the native monomer. Of note,
D45A/Y118F was also observed to spontaneously oligomerize (Supp Fig. 3.7.2) as well as had a
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higher propensity to precipitate in solution during purification, which is indicative of altered
protein folding.
We hypothesized that the immune system may recognize these antigens differently due to
the binding and structural changes and therefore potentially process and respond differently. We
also utilized two distinct FDA-approved adjuvant formulations, GSK AS03-like and GSK AS04like formulations, as the adjuvant properties combined with the differing mutant antigen
properties may elicit different responses. Our data shows the following: 1) all vaccine candidates
are highly effective in both adjuvant formulations against S. aureus skin infection compared to
the sham controls; 2) adjuvating H35L and H35L/R66C/E70C in either formulation provides
similar and the best protection; 3) H35L/R66C/E70C had the highest antibody titer and toxin
neutralization capability; 4) antigen H35L/D45A/Y118F provides differential protection
compared to H35L and H35L/R66C/E70C in both adjuvants. Interestingly, mice immunized with
H35L/D45A/Y118F in the AS04-like formulation had significantly larger abscess and
dermonecrotic lesions compared to the other antigens in both formulations. This phenotype is the
most evident within the first 48 hours post infection, however, the abscesses remained larger
compared to the H35L and H35L/R66C/E70C abscesses throughout the duration of the
experiment. In addition, the dermonecrotic lesions were significantly larger, measuring up to
20mm2 where the other antigens maximum measurements stayed under 10-15mm2 in both
formulations.
Clinically speaking, all antigens and adjuvant combinations provide efficient protection
against S. aureus skin infection, however, the antibody titers and neutralization capability of each
of the antigens highlighted the discrepancies in the elicited immune response. The mutants
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adjuvanted with the AS03-like formulations overall produced a more robust antibody response as
the EC50 titers of each antigen are 2-fold higher than in the AS04-like formulation. Furthermore,
H35L/R66C/E70C also had a 2-fold higher antibody titer compared to the other antigens. The
overall toxin neutralizing capability of the antigens combined with the AS03-like formulations
were overall higher than the AS04-like formulations. H35L/R66C/E70C showed a remarkable
neutralizing capability as the serum could be diluted 34-fold more than H35L serum and 658fold more than H35L/D45A/Y118F serum and still provide 50% toxin neutralization.
Both H35L and H35L/R66C/E70C performed similarly and were overall the more
effective vaccine candidates, in spite of their differences in receptor binding properties. In
addition, H35L/D45A/Y118F retains some binding to the host receptor but the monomeric
structure is structurally less compact and behaves very differently compared to wild-type Hla,
H35L or H35L/R66C/E70C. Furthermore, H35L/D45A/Y118F spontaneously oligomerizes
which may also impact immunogenicity due to the toxin aggregates potentially covering useful
epitopes. We also have preliminary data that showed Hla mutants adjuvanted with the AS03-like
formulation overall induced a better CD4+ memory T cell response, with H35L/R66C/E70C
inducing even more of these cells compared to all other antigens. Furthermore, mice that
received AS03-like sham immunizations overall had larger lesions than mice that received
AS04-like sham immunizations, suggesting that AS03-like adjuvants are potent immune
stimulators. Together this data suggests that the host immune response is recognizing and
processing these antigens differently and responding more effectively in combination with the
AS03 formulation.
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It is possible that the H35L/R66C/E70C antigen may elicit a more robust immune
response by virtue of its ability to preserving the native monomeric structure of the toxin while
rendering it unable to bind to the host receptor. Based on all data available to date, we made the
following hypotheses: 1) a soluble antigen may lead to more antigen available within the tissue
microenvironment to get taken up and processed specifically by professional antigen presenting
cells; 2) the Hla-ADAM10 complex may play a role in how the host immune system recognizes
and processes the antigen; 3) toxin mutant antigens that preserve native structure of the toxin
may be important for useful epitope recognition. The increased antibody titer and CD4 memory
T cell response observed with antigen H35L/R66C/E70C may be the result of more soluble
antigen available for internalization specifically by professional APCs via endocytic pathways.
For example, dendritic cells constitutively use macropinocytosis to sample the local environment
in order to initiate the adaptive immune response through MHC-II antigen presentation to CD4+
T cells. While the H35L antigen provides similar protection against S. aureus skin infection to
H35L/R66C/E70C, the antibody titer, neutralizing capability and CD4+ T memory response were
significantly lower. The cause of this reduction could be two-fold: first, H35L antigen binds to
ADAM10, which is on almost every cell type and therefore may reduce the available antigen to
be taken up by professional APCs. Thus, ADAM10 expression on non-professional APCs and
other cells such as the keratinocytes or epithelial cells could be acting as an 'antigen sink'.
Second, antigen bound to ADAM10 taken up by these other cells would most likely be processed
and presented through MHC-I to activated CD8+ T cells rather than CD4+ T cells, which could
explain the decrease in antibody response. Furthermore, it is interesting to speculate that the HlaADAM10 complex could be internalized together and processed more like a self-antigen through
normal membrane recycling pathways and reduce the amount of Hla antigen properly presented.
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One way we could test if a soluble Hla antigen is more effective than a cell bound Hla antigen, is
by immunizing wild-type and ADAM10-/- mice with H35L. The loss of ADAM10 expression in
the ADAM10-/- would result in soluble H35L and may improve antibody responses compared to
wild-type H35L immunized mice.
In conclusion, our studies have demonstrated that immunization with three distinct
candidate vaccine antigens provided significant protection against S. aureus skin infection yet
elicited distinguishable immune responses. Not only did the structural and binding properties of
the Hla antigens play a role but the type of adjuvant used in combination with the antigens
impacted vaccine efficacy. Our lab has previously shown that Hla hampers the T cell response,
utilizing an antigen that elicits a high neutralizing capability like H35L/R66C/E70C could be the
key to preserving the T cell compartment. These studies could provide valuable insight not only
for vaccine design but also shed light on how bacterial toxins that bind host receptors are
recognized and processed differently than other antigens. Lastly, we have generated an
ADAM10 knock-in system on mouse red blood cells that will allow us to visualize the HlaADAM10 complex for the first time through advanced microscopy techniques. Identifying the
exact mechanism and structural interface between the toxin and receptor would provide
important implications for therapeutic approaches and could provide greater insight on the
biologic function of pore-forming toxins in general.

3.5 Materials and Methods
Plasmid Construction and Hla Antigen Purification
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Toxin variants (double and triple mutants) were cloned into the pET24b expression vector
containing a C-terminal polyhistidine tag. PCR products were amplified from Hla template from
DNA constructs previously generated in the Bubeck Wardenburg lab. Vector and mutant insert
ligation reactions were transformed into Escherichia coli DH5 alpha, colonies screened for
positive clones and each construct sequenced for verification. Confirmed clones were then
transformed into E. coli BL21 for recombinant protein expression and purification. Generation of
recombinant polyhistidine-tagged wildtype Hla and HlaH35L (H35L) have been described
previously 77. Recombinant toxin variants were prepared and purified using standard protocols,
LPS extracted and evaluated by 10% SDS-polyacrylamide gel electrophoresis (PAGE) followed
by Coomassie blue staining.

Hla activity assay (rRBC hemolysis)
Rabbit red blood cell (rRBC) hemolysis was assayed by incubation of rRBCs (Hemostat Labs)
with purified toxin variants ranging from 300-0.14 nM for 1 hour at room temperature.
Following incubation, cells were pelleted by centrifugation and supernatant absorbance at 450nm
measured. Percent rRBC hemolysis were calculated relative to 1% Triton X-100 maximal lysis
controls. The assays were performed in triplicate and repeated for reproducibility on separate
days.

rRBC binding and oligomerization assays
Radiolabeled Hla was synthesized by in vitro transcription and translation in an E. coli S30
extract (Promega) supplemented with T7 RNA polymerase, rifampin (rifampicin), and [35S]
methionine according to the manufacturer's instructions. For the binding assay, one hundred
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twenty microliters of 12.5% rabbit red blood cells (rRBC) in K-PBSA/βME (20 mM potassium
phosphate [monobasic], 150 mM NaCl [pH 7.4], 1 mg/ml bovine serum albumin, 1 mM βmercaptoethanol) was incubated with 10 μl of radiolabeled Hla mixture for 5 minutes at room
temperature. Cells were pelleted, washed twice with ice-cold PBS, resuspended in 200μl of PBS
and added to scintillation fluid. Radioactivity from cell bound toxin was quantified on a
Beckman LS6000 scintillation counter. For oligomerization assays, rRBCs were used as
described above but incubated with 30 μl of the radiolabeled Hla mixture (~ 1 nM) for 1 h at
room temperature. Following incubation, cells were pelleted and washed with 500 μl KPBSA/βME and then resuspended in 90 μl 1× Laemmli buffer. Samples were divided into 30 μl
aliquots and incubated at 37°C, 60°C and 80°C for 10 min before samples were loaded onto 10%
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) gels for
electrophoresis. The gels were dried, and then the results were visualized using a
phosphorimager. Binding assays were performed in triplicate and repeated for reproducibility on
separate days. Oligomerization assays were performed with a single replicate and repeated for
reproducibility on separate days.

Thermal Shift Assay
The stability of protein was measured by the melting temperature of each protein (50%
denaturation point). Each well contained a final concentration of 5 μM protein, 4.5 × Sypro
Orange, and 1x buffer (20 mM Tris pH 7.5, 150 mM NaCl). The plates were heated in
StepOnePlus™ Real-Time PCR System (Thermo Fisher) from 20 to 90 °C in increments of
0.3°C. The wavelengths for excitation and emission were 490 and 575 nm, respectively.

Immunization and S. aureus skin infection
46

All animal experiments were reviewed, approved, and supervised by the Institutional Animal
Care and Use Committee (IACUC) at Washington University at St. Louis. Hla antigens were
LPS extracted and prepared with either AS03-like adjuvant formulation, 1:1 antigen to AddaS03
(InvivoGen, Cat # 10253-42-02) or AS04-like formulation with antigen plus 500 µg/mL
Alhydrogel (InvivoGen, cat# vac-alu-250) and 50 µg/mL of MPLA-SM VacciGrade (InvivoGen,
cat# vac-mpla). 20 micrograms of each antigen were delivered intramuscularly to cohorts of ten
3-week-old C57BL/6 male mice (Jackson Laboratory) on days 0 and 14. For SSTI modeling, on
day 21 mice were anesthetized via intraperitoneal injection of ketamine (20 mg/kg) and xylazine
(5 mg/kg) followed by right flank subcutaneous challenge with 1x108 CFU S. aureus strain
USA300/LAC in 50 µL PBS 71. Lesional abscess and dermonecrosis area (mm2) was measured
at 24-hour intervals for 7 days. Abscess and dermonecrosis size was determined according to the
formula A=(π/2)(length mm)(width mm) 42,79. Naïve serum was collected from 5 mice on day 0
and 14 prior to S. aureus challenge to determine antibody titers following immunization.

ELISA and Antibody Neutralization Assays
Sera collected from immunized mice was diluted 1:25 and then four-fold serial dilutions for
eight dilutions total. Anti-Hla titers were determined by ELISA as previously described78 and
ELISA absorbance readings (450nm) used for generation of four-parameter log(dose)-response
curves using Prism software. For the neutralization assay, the serum was diluted 1:100 and then
two-fold for eight dilutions total. The diluted serum was incubated with toxin for 15 minutes at
room temperature before 2.5x108 c/ml of rabbit red cells were added. The final concentration of
toxin was 2nM and the assay incubated at room temperature for 1 hour. Cells were pelleted and
supernatant absorbance readings (450nm) were used to generate non-linear regression curves
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with log (inhibitor) vs. response – variable slope curves using GraphPad Prism software. Both
the ELISA and neutralization assays were performed in triplicate.

Generation of VavCre+/- bAdam10+ mice
Mice harboring the bovine Adam10 transgene were generated using a Cre-inducible knock-in
system. The transgenic cassette includes a CAG promoter followed by LoxP flanked eGFP and a
bovine poly-adenosine site. eGFP cDNA and the poly-adenosine site will be excised upon Cre
recombination and allow the dormant transgene to be expressed (Fig. 3.3.6A). Bovine Adam10
constructs were generated by PCR and include a carboxyl-terminus human influenza
hemagglutinin tag. The construct was sequence confirmed using bovine Adam10 primers and
prepared according to instructions by the Transgenic Mouse and Embryonic Stem Cell Facility at
The University of Chicago for ES injection. F0 progeny were screened for the presence of the
bovine Adam10 transgene via GFP signal using a BlueStar Flashlight (NightSea). F0 males and
females expressing GFP were crossed to C57BL6 mice to generate F1 progeny. F1 mice were
then crossed to homozygous Adam10 floxed allele mice (Adam10loxP/loxP). Progeny were
screened by PCR for the Adam10 floxed allele and for the presence of GFP. Mice heterozygous
for the Adam10 floxed allele and positive for the bovine Adam10 transgene were crossed to
generate homozygous Adam10 floxed and bovine Adam10 transgene positive mice
(Adam10loxP/loxP/bAdam10). Tissue-specific experimental mice utilized in the mouse red blood
cells isolation studies were generated by crossing Adam10loxP/loxP/bAdam10 mice to Vav-Cre
(The Jackson Laboratory). Mice were then screened for Vav-Cre and the bAdam10 transgene
cassette (VavCre+/- bAdam10+).

VavCre+/- bAdam10+ mouse red blood cells
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Blood isolation: Whole blood was collected by submandibular puncture using 5 mm Goldenrod
Animal Lancets and diluted with five mLs of PBS. To isolate the red blood cells, the whole
blood was centrifuged at 500xg for 10 minutes and washed three times with PBS. The red blood
cells were then resuspended in PBS, counted and diluted to the necessary concentration for the
assays. For the hemolysis assay, 2.5x108 cells/mL were incubated with 2nM of purified Hla toxin
for 1 hour at room temperature. Following incubation, cells were pelleted by centrifugation and
supernatant absorbance 450nm was measured. Percent RBC hemolysis were calculated relative
to 1% Triton X-100 maximal lysis controls. For the radiolabeled binding assay, 5x108 cells were
incubated for 5 minutes at room temperature with approximately 1 nM of [35S] methionineradiolabeled toxin and performed as described above. The assays were performed in triplicate
and repeated for reproducibility on separate days.

Statistical analysis
Statistical analysis was performed on GraphPad Prism software using one-way ANOVA with
Tukey’s multiple comparison test, significance level 0.05. Assessment of statistical significance
in skin infection studies was performed on GraphPad Prism software using Multiple unpaired T
tests, p < 0.05.
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Figure 3.3.1: Hla mutant characterization: rRBC Lysis
Activity of Hla double (A) and triple (B) mutant variants was assessed via rabbit RBC lysis.
Rabbit RBCs were incubated across a range of toxin concentrations for one hour at room
temperature. Absorbance at 475nm of reaction supernatants was measured and percent lysis was
calculated relative to detergent maximal lysis controls (0.1% Triton X-100).
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Figure 3.3.2. Hla mutant characterization: Binding and Oligomerization Capacity
* Mutant abbreviations are as follows: HDY (H35L/D45A/Y118F), HRE (H35L/R66C/E70C).
A. Each toxin variant was assessed for the binding capacity to rRBCs. Each toxin was
incubated with rRBCs cells for 5 minutes, pelleted, supernatants removed and
radiolabeled toxin in the cellular fraction assessed by detection of 35S cpm. One-way
ANOVA with Tukey’s multiple comparison test was performed using GraphPad Prism
software, p < 0.05.
B. Toxin pore assembly, formation, and stability was examined for each variant. 35S
radiolabeled mutant toxins were incubated with rabbit RBCs for one hour at room
temperature followed by additional incubation at 37°C, 60°C, or 80°C for 10 minutes.
Samples were separated by SDS-PAGE followed by phosphor-imaging for detection of
high molecular weight oligomers. Toxin monomers are denoted by the arrow and toxin
oligomers denoted by Hla7.
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Figure 3.3.3: Structural and stability analysis
The structural changes and stability of each toxin variant was compared to the wild-type toxin.
Five μM of each mutant was incubated with Sypro Orange dye and assay buffer. The melting
curves and Melting Temperatures (table) was measured by heating the plates in a StepOnePlus™
Real-Time PCR System (Thermo Fisher) from 20 to 90 °C in increments of 0.3°C. The
wavelengths for excitation and emission were 490 and 575 nm, respectively.
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Figure 3.3.4: Hla mutants and adjuvants provide differential vaccine protection
Mice were vaccinated with Hla variants H35L, H35L/D45A/Y118F, H35L/R66C/E70C or
adjuvants alone and challenged subcutaneously with 1x108 S. aureus strain USA300. The left
panels of figures A and B represent immunizations with AS03-like formulations (solid lines), the
right side of both figures represent immunizations with AS04-like formulations (dotted lines).
Lesion abscess and dermonecrosis area was measured at 24-hour intervals for 7 days. Figure A
includes the sham controls and Figure B only includes immunized groups with statistical
analyses. Multiple unpaired T tests were performed on GraphPad Prism software, p < 0.05.
Asterisks show significant differences comparing H35L/D45A/Y1118F (aqua) to H35L
(lavender) and H35L/R66C/E70C (orange).
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Figure 3.3.5: Antibody titers and neutralization
A. Naïve serum was collected on days 0 and 14 prior to infection and Hla ELISAs
performed with serially diluted sera. ELISA absorbance readings were used to generate
four-parameter log(dose)-response curves using Prism software for EC50 titer
extrapolation. One-way ANOVA was performed with GraphPad Prism software using
Tukey’s multiple comparison test, p < 0.05.
B. To determine toxin neutralization capacity of the serum, toxin was incubated with serially
diluted sera for 1 hour at room temperature and then added to rRBCs. Absorbance at
475nm of reaction supernatants was measured and percent lysis was calculated relative to
detergent maximal lysis controls (0.1% Triton X-100). Absorbance readings were used to
generate four-parameter log(dose)-response curves using Prism software for EC50 titer
extrapolation.
C. Plot of serologic protection from Hla-induced rabbit red cell lysis as a function of antiHla serum EC50 titer from vaccinated mice.

55

A
loxP
CAG promoter

loxP
EGFP pA

bAdam10 pA

EGFP pA
Vav1 iCre

loxP

bAdam10 pA

CAG promoter

C

B

**

40

**

4000

RBC % Lysis

CPM Hla Binding

5000

3000
2000

30
20
10
0

1000
WT

VavCre

+

WT
+

VavCre+
+

bAdam10

bAdam10

Figure 3.3.6 VavCre+/- bAdam10+ mouse red blood cells are sensitized to Hla

A. Genetic strategy to generate mice harboring a Cre-induced deletion of endogenous mouse

Adam10 and Cre-inducible knock-in of bAdam10 in hematopoietic and progenitor cells
using a Vav1 promoter-driven Cre recombinase.
B. Red blood cells isolated from VavCre+/- bAdam10+ and control mice were assessed for
the binding of [35S] radiolabeled Hla toxin. Cells were incubated for 5 minutes with
radiolabeled toxin at room temperature. Cells were washed and pelleted, supernatants
removed and radiolabeled toxin in the cellular fraction assessed by detection of 35S cpm.
C. Red blood cells isolated from VavCre+/- bAdam10+and control mice were assessed for the
Hla toxin sensitivity. Cells were incubated with toxin for 1 hour at room temperature.
Absorbance at 475nm of reaction supernatants was measured and percent lysis was
calculated relative to detergent maximal lysis controls (0.1% Triton X-100).
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Supplemental Figure 3.7.1: Purified Hla mutants
(Left panel) Purified Hla proteins were separated by 10% SDS-PAGE and stained with
InstantBlue coomassie stain for 15 minutes to confirm protein size and purity.
Supplemental Figure 3.7.2: [35S] methionine labeled Hla mutants
(Right panel) [35S] methionine labeled Hla toxins were generated using in vitro transcription and
translation. Toxins were separated by 10% SDS-PAGE and developed by phoshorimaging to
confirm protein size and purity.
* Mutant abbreviations are as follows: HDY (H35L/D45A/Y118F), HRE (H35L/R66C/E70C)
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